The Weave Bio Strategic Advisory Board brings together leaders across pharma, academia, and capital markets. This group helps guide the responsible use of AI in regulatory science. It also marks an important step as Weave continues building a human-driven, AI-enabled platform across the therapeutic lifecycle.
The formation of the Weave Bio Strategic Advisory Board reflects a broader shift in how teams apply AI in regulatory science. As expectations evolve, organizations must combine deep regulatory expertise with AI development. This ensures accuracy, trust, and scientific rigor.
By bringing together leaders from across the ecosystem, Weave builds with direct input from experts shaping regulatory strategy, policy, and innovation today.
What this means for regulatory science
Today, AI plays a growing role in regulatory science. As a result, organizations must ensure these systems align with regulatory expectations, scientific standards, and real-world workflows.
In addition, the advisory board connects industry practice with product development. Its members bring firsthand experience working with health authorities and leading innovation in global pharma organizations. This helps ensure the Weave platform reflects how regulatory work happens today while supporting where the field is going.
As the platform evolves, the board will help guide how teams apply AI across the regulatory lifecycle—from early development through clinical and post-market activities. Throughout this process, accuracy, transparency, and trust remain central.
Looking ahead
Looking ahead, the Weave Bio Strategic Advisory Board will continue to support the platform’s expansion across the regulatory lifecycle. As AI reshapes regulatory work, maintaining alignment with industry expectations will remain critical.
At the same time, Weave will continue building technology that reflects how regulatory teams operate today. The board’s insights will help ensure that AI development stays grounded in practical application and real-world impact.